Gene Therapy for Age-related Macular Degeneration -A Pipeline Analysis Report
This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy molecules for age-related macular degeneration in the development and pre-clinical stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.
Technavio’s market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020.
Key questions answered in the report include
What are the different stages of the pipeline molecules under investigation?
What are the gene therapy molecules in the various development stages for age-related macular degeneration?
What are the companies that are currently involved in the development of gene therapy molecules for age-related macular degeneration?
What are the molecules discontinued from development?
What are the major regulatory authorities approving drugs in various regions?